NO963029L - Use of IL-10 to stimulate cytological activity of single-core peripheral blood cells - Google Patents

Use of IL-10 to stimulate cytological activity of single-core peripheral blood cells

Info

Publication number
NO963029L
NO963029L NO963029A NO963029A NO963029L NO 963029 L NO963029 L NO 963029L NO 963029 A NO963029 A NO 963029A NO 963029 A NO963029 A NO 963029A NO 963029 L NO963029 L NO 963029L
Authority
NO
Norway
Prior art keywords
peripheral blood
stimulate
blood cells
core peripheral
cytological activity
Prior art date
Application number
NO963029A
Other languages
Norwegian (no)
Other versions
NO963029D0 (en
Inventor
Martin A Schwarz
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of NO963029D0 publication Critical patent/NO963029D0/en
Publication of NO963029L publication Critical patent/NO963029L/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2013—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2066—IL-10
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
    • A61K2239/48—Blood cells, e.g. leukemia or lymphoma

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

Denne oppfinnelsen vedrører anvendelse av IL-10, alene eller i kom- binasjon med IL-2 og/eller a-lFN, til å behandle neoplasmasykdommer ved å sti- mulere cytolytisk aktivitet av mono- nukleære celler fra perifert blod.This invention relates to the use of IL-10, alone or in combination with IL-2 and / or α-IFN, to treat neoplasmic diseases by stimulating cytolytic activity of peripheral blood mononuclear cells.

NO963029A 1994-01-20 1996-07-19 Use of IL-10 to stimulate cytological activity of single-core peripheral blood cells NO963029L (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN94194863A CN1142186A (en) 1994-01-20 1994-01-20 Use of IL-10 to stimulate peripheral blood mononuclear cell cytolytic activity
PCT/IB1994/000008 WO1995019780A1 (en) 1994-01-20 1994-01-20 Use of il-10 to stimulate peripheral blood mononuclear cell cytolytic activity

Publications (2)

Publication Number Publication Date
NO963029D0 NO963029D0 (en) 1996-07-19
NO963029L true NO963029L (en) 1996-09-19

Family

ID=37708148

Family Applications (1)

Application Number Title Priority Date Filing Date
NO963029A NO963029L (en) 1994-01-20 1996-07-19 Use of IL-10 to stimulate cytological activity of single-core peripheral blood cells

Country Status (10)

Country Link
EP (1) EP0740552A1 (en)
JP (1) JPH09508116A (en)
CN (1) CN1142186A (en)
AU (1) AU707019B2 (en)
FI (1) FI962813A (en)
NO (1) NO963029L (en)
NZ (1) NZ259584A (en)
PL (1) PL175343B1 (en)
SK (1) SK91696A3 (en)
WO (1) WO1995019780A1 (en)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002532556A (en) * 1998-12-22 2002-10-02 シェリング・コーポレーション Treatment of hepatitis C virus infection with interleukin-10
WO2002026265A2 (en) 2000-09-29 2002-04-04 Schering Corporation Pegylated interleukin-10
RU2322452C2 (en) * 2006-03-27 2008-04-20 Михаил Николаевич Смирнов Immunomodulating composition
AU2007314501B2 (en) 2006-09-28 2013-05-23 Merck Sharp & Dohme Corp. Use of pegylated IL-10 to treat cancer
CA2692282A1 (en) * 2007-06-27 2008-12-31 Joslin Diabetes Center, Inc. Regulatory t cells in adipose tissue
RU2549702C2 (en) 2008-12-17 2015-04-27 Мерк Шарп И Доум Корп., Preparing and using mono- and di-pegylated il-10
CN106913865A (en) 2013-04-18 2017-07-04 阿尔莫生物科技股份有限公司 The method that disease and illness are treated using interleukin 10
EP3010527B1 (en) 2013-06-17 2018-08-08 Armo Biosciences, Inc. Method for assessing protein identity and stability
CN105658232A (en) 2013-08-30 2016-06-08 阿尔莫生物科技股份有限公司 Methods of using interleukin-10 for treating diseases and disorders
RU2016122957A (en) 2013-11-11 2017-12-19 Армо Байосайенсиз, Инк. Methods of using interleukin-10 for the treatment of diseases and disorders
WO2015187295A2 (en) 2014-06-02 2015-12-10 Armo Biosciences, Inc. Methods of lowering serum cholesterol
AU2015333827A1 (en) 2014-10-14 2017-04-20 Armo Biosciences, Inc. Interleukin-15 compositions and uses thereof
KR20170084033A (en) 2014-10-22 2017-07-19 아르모 바이오사이언시스 인코포레이티드 Methods of using interleukin-10 for treating diseases and disorders
WO2016126615A1 (en) 2015-02-03 2016-08-11 Armo Biosciences, Inc. Methods of using interleukin-10 for treating diseases and disorders
WO2016191587A1 (en) 2015-05-28 2016-12-01 Armo Biosciences, Inc. Pegylated interleukin-10 for use in treating cancer
WO2017035232A1 (en) 2015-08-25 2017-03-02 Armo Biosciences, Inc. Methods of using interleukin-10 for treating diseases and disorders
IL312238A (en) * 2021-10-25 2024-06-01 Ellennbe Gmbh Pharmaceutical composition and kit comprising an immunomodulatory substance for treating diseases

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0567586T3 (en) * 1991-01-16 1995-12-04 Schering Corp Use of interleukin-10 in adoptive cancer immunotherapy
KR100207766B1 (en) * 1991-01-16 1999-07-15 둘락 노먼 씨. Interleukin-10 composition for treating neoplastic disease
US5055045A (en) * 1991-03-18 1991-10-08 Dickie Robert G Disposable dental matrix retainer clamp

Also Published As

Publication number Publication date
SK91696A3 (en) 1997-04-09
PL315513A1 (en) 1996-11-12
NZ259584A (en) 1998-01-26
AU5842594A (en) 1995-08-08
FI962813A0 (en) 1996-07-11
AU707019B2 (en) 1999-07-01
JPH09508116A (en) 1997-08-19
NO963029D0 (en) 1996-07-19
EP0740552A1 (en) 1996-11-06
WO1995019780A1 (en) 1995-07-27
CN1142186A (en) 1997-02-05
PL175343B1 (en) 1998-12-31
FI962813A (en) 1996-07-11

Similar Documents

Publication Publication Date Title
NO963029L (en) Use of IL-10 to stimulate cytological activity of single-core peripheral blood cells
EA200600076A1 (en) COMPOSITIONS AND METHODS OF INCREASING THE ACTIVITY OF TELOMERASE
DE69030880D1 (en) Composition for stimulating the immune system
NO990916D0 (en) Use of GLP-1 or analogues in the treatment of myocardial infarction
FI844510L (en) ENSYM-RESISTANT IMMUNSYSTEMET MODULERANDE PEPTIDER.
FR2777183B1 (en) USE OF AT LEAST ONE HYDROXYSTILBENE IN A COMPOSITION FOR PROMOTING DEQUAMATION OF THE SKIN AND COMPOSITION COMPRISING SAME
NZ332720A (en) Therapeutic uses of bactericidal/permeability increasing (BPI) protein to treat human meningococcemia
EP0211354A3 (en) Nucleosides and their use as antineoplastic agents
GR1002802B (en) Cosmetic compositions and skin treatment compositions
GB2187955B (en) Improvements in or relating to the treatment of sickle cell disease
DE69725882D1 (en) ADENOVIRUS E4 PROTEINS FOR INDUCTION OF CELL DEATH
ATE81467T1 (en) IMMUNOSUPPRESSION IN IMMUNOTOXIN-BASED TREATMENT OF HUMANS.
BG101126A (en) The use of muramylpeptide compounds
MXPA00010254A (en) The treatment of sexual dysfunction in certain patient groups.
HU9201197D0 (en) Protection from shock subsequent to injury by double-stranded rns
EP0967276A3 (en) Anti-tumor agent comprising salmosin
MY131599A (en) Use of il-10 to stimulate peripheral blood mononuclear cell cytolytic activity
PT1032402E (en) USE OF CITICOLIN FOR THE TREATMENT OF MULTIPLE SCLEROSIS
WO2005094282A3 (en) Combination therapy comprising cloretazinetm
EP0668771A4 (en) Treatment of autoimmune diseases by inducing tolerance to cells, tissues and organs.
ZA873928B (en) Topical methotrexate preparation for the treatment of hyperproliferative epithelial disease
DE3374066D1 (en) N-acyl derivatives of peptides, their manufacture and use in combating diseases and means therefor
JPS6485990A (en) Antihypertestoeronemia agent
IL136807A0 (en) Topical carbamazepine formulation and methods of use
EP0321094A3 (en) Treatment of factor viii inhibitors